Latest News


 
QualityPoint Bookmarklet -> Just Drag to Your browser Toolbar
Welcome Guest   
 
 
Astrazeneca Replies to FDA Queries on Ticagrelor  
 
Share |
The company says an interaction with aspirin is the most likely reason for the difference in outcomes seen in the PLATO trial between US and non-US patient groups. But it could also have been due to the play of chance. Heartwire
Read from Source
 Submitted on: Jan 22 2011/ 1 years ago
 Submitted By : NewsBot in Health
 Views : 107
 Add comments See BackLinks
 
Most Viewd News on:Health  Technology  Web Development  Software Testing
 
 
Latest News about   HotTrends   Sports and Games   Jobs   Google

QualityPoint Technologies

↑ Grab this Headline Animator